(Neo-)adjuvant ipilimumab + nivolumab (IPI+NIVO) in palpable stage 3 melanoma – updated relapse free survival (RFS) data from the OpACIN trial and first biomarker analyses
Gespeichert in:
| Veröffentlicht in: | Annals of oncology 2017-09, Vol.28, p.v432-v432 |
|---|---|
| Hauptverfasser: | , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | v432 |
|---|---|
| container_issue | |
| container_start_page | v432 |
| container_title | Annals of oncology |
| container_volume | 28 |
| creator | Rozeman, E.A. Fanchi, L. van Akkooi, A.C.J. Kvistborg, P. Thienen, J.V. Stegenga, B. Lamon, B. Haanen, J.B. Schumacher, T.N.M. Blank, C.U. |
| description | |
| doi_str_mv | 10.1093/annonc/mdx377.008 |
| format | Article |
| fullrecord | <record><control><sourceid>elsevier_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1093_annonc_mdx377_008</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0923753420384842</els_id><sourcerecordid>S0923753420384842</sourcerecordid><originalsourceid>FETCH-LOGICAL-c1858-9e4e6d6e631f6549cd4bf388889427bc3849b66fba40ad1cb79b80bd6039eac23</originalsourceid><addsrcrecordid>eNp9UMtuFDEQtBCRWAIfwK2Pu4omsdeznrE4RasERop2o_C4jtp2DzjMS_bsiNz4B74jP8WXxGQ505duVVeVSsXYO8HPBdfyAvt-6O1F537KojjnvHzBFmKjdFbyXLxkC67XMis2Mn_FXsd4zzlXeq0X7HG5oyFbobs_zNhP4Eff-u7QoYEz6P08tM_3srqtznbV1_0KfA8jtiOaliBO-I1AQkct9kOH8OfXbziMDidyEBI4RoImUGIewuxnbGF5d_1pBYmB6TF0MH0n2I-X22oHU_CJgL2Dxoc4gfHJMvygkDBsHyLFN-ykwTbS23_7lH25vvq8_Zjd7D9U28ubzIpyU2aaclJOkZKiUZtcW5ebRpZpdL4ujJVlro1SjcGcoxPWFNqU3DjFpSa0a3nKxNHXhiHGQE09Bp-yPNSC13_7ro9918e-69R30rw_aigFmz2FOlpPvSXnA9mpdoP_j_oJ98iNFg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>(Neo-)adjuvant ipilimumab + nivolumab (IPI+NIVO) in palpable stage 3 melanoma – updated relapse free survival (RFS) data from the OpACIN trial and first biomarker analyses</title><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Alma/SFX Local Collection</source><creator>Rozeman, E.A. ; Fanchi, L. ; van Akkooi, A.C.J. ; Kvistborg, P. ; Thienen, J.V. ; Stegenga, B. ; Lamon, B. ; Haanen, J.B. ; Schumacher, T.N.M. ; Blank, C.U.</creator><creatorcontrib>Rozeman, E.A. ; Fanchi, L. ; van Akkooi, A.C.J. ; Kvistborg, P. ; Thienen, J.V. ; Stegenga, B. ; Lamon, B. ; Haanen, J.B. ; Schumacher, T.N.M. ; Blank, C.U.</creatorcontrib><identifier>ISSN: 0923-7534</identifier><identifier>EISSN: 1569-8041</identifier><identifier>DOI: 10.1093/annonc/mdx377.008</identifier><language>eng</language><publisher>Elsevier Ltd</publisher><ispartof>Annals of oncology, 2017-09, Vol.28, p.v432-v432</ispartof><rights>2017 European Society for Medical Oncology</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c1858-9e4e6d6e631f6549cd4bf388889427bc3849b66fba40ad1cb79b80bd6039eac23</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27903,27904</link.rule.ids></links><search><creatorcontrib>Rozeman, E.A.</creatorcontrib><creatorcontrib>Fanchi, L.</creatorcontrib><creatorcontrib>van Akkooi, A.C.J.</creatorcontrib><creatorcontrib>Kvistborg, P.</creatorcontrib><creatorcontrib>Thienen, J.V.</creatorcontrib><creatorcontrib>Stegenga, B.</creatorcontrib><creatorcontrib>Lamon, B.</creatorcontrib><creatorcontrib>Haanen, J.B.</creatorcontrib><creatorcontrib>Schumacher, T.N.M.</creatorcontrib><creatorcontrib>Blank, C.U.</creatorcontrib><title>(Neo-)adjuvant ipilimumab + nivolumab (IPI+NIVO) in palpable stage 3 melanoma – updated relapse free survival (RFS) data from the OpACIN trial and first biomarker analyses</title><title>Annals of oncology</title><issn>0923-7534</issn><issn>1569-8041</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><recordid>eNp9UMtuFDEQtBCRWAIfwK2Pu4omsdeznrE4RasERop2o_C4jtp2DzjMS_bsiNz4B74jP8WXxGQ505duVVeVSsXYO8HPBdfyAvt-6O1F537KojjnvHzBFmKjdFbyXLxkC67XMis2Mn_FXsd4zzlXeq0X7HG5oyFbobs_zNhP4Eff-u7QoYEz6P08tM_3srqtznbV1_0KfA8jtiOaliBO-I1AQkct9kOH8OfXbziMDidyEBI4RoImUGIewuxnbGF5d_1pBYmB6TF0MH0n2I-X22oHU_CJgL2Dxoc4gfHJMvygkDBsHyLFN-ykwTbS23_7lH25vvq8_Zjd7D9U28ubzIpyU2aaclJOkZKiUZtcW5ebRpZpdL4ujJVlro1SjcGcoxPWFNqU3DjFpSa0a3nKxNHXhiHGQE09Bp-yPNSC13_7ro9918e-69R30rw_aigFmz2FOlpPvSXnA9mpdoP_j_oJ98iNFg</recordid><startdate>201709</startdate><enddate>201709</enddate><creator>Rozeman, E.A.</creator><creator>Fanchi, L.</creator><creator>van Akkooi, A.C.J.</creator><creator>Kvistborg, P.</creator><creator>Thienen, J.V.</creator><creator>Stegenga, B.</creator><creator>Lamon, B.</creator><creator>Haanen, J.B.</creator><creator>Schumacher, T.N.M.</creator><creator>Blank, C.U.</creator><general>Elsevier Ltd</general><scope>6I.</scope><scope>AAFTH</scope><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>201709</creationdate><title>(Neo-)adjuvant ipilimumab + nivolumab (IPI+NIVO) in palpable stage 3 melanoma – updated relapse free survival (RFS) data from the OpACIN trial and first biomarker analyses</title><author>Rozeman, E.A. ; Fanchi, L. ; van Akkooi, A.C.J. ; Kvistborg, P. ; Thienen, J.V. ; Stegenga, B. ; Lamon, B. ; Haanen, J.B. ; Schumacher, T.N.M. ; Blank, C.U.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c1858-9e4e6d6e631f6549cd4bf388889427bc3849b66fba40ad1cb79b80bd6039eac23</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Rozeman, E.A.</creatorcontrib><creatorcontrib>Fanchi, L.</creatorcontrib><creatorcontrib>van Akkooi, A.C.J.</creatorcontrib><creatorcontrib>Kvistborg, P.</creatorcontrib><creatorcontrib>Thienen, J.V.</creatorcontrib><creatorcontrib>Stegenga, B.</creatorcontrib><creatorcontrib>Lamon, B.</creatorcontrib><creatorcontrib>Haanen, J.B.</creatorcontrib><creatorcontrib>Schumacher, T.N.M.</creatorcontrib><creatorcontrib>Blank, C.U.</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>CrossRef</collection><jtitle>Annals of oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Rozeman, E.A.</au><au>Fanchi, L.</au><au>van Akkooi, A.C.J.</au><au>Kvistborg, P.</au><au>Thienen, J.V.</au><au>Stegenga, B.</au><au>Lamon, B.</au><au>Haanen, J.B.</au><au>Schumacher, T.N.M.</au><au>Blank, C.U.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>(Neo-)adjuvant ipilimumab + nivolumab (IPI+NIVO) in palpable stage 3 melanoma – updated relapse free survival (RFS) data from the OpACIN trial and first biomarker analyses</atitle><jtitle>Annals of oncology</jtitle><date>2017-09</date><risdate>2017</risdate><volume>28</volume><spage>v432</spage><epage>v432</epage><pages>v432-v432</pages><issn>0923-7534</issn><eissn>1569-8041</eissn><pub>Elsevier Ltd</pub><doi>10.1093/annonc/mdx377.008</doi><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0923-7534 |
| ispartof | Annals of oncology, 2017-09, Vol.28, p.v432-v432 |
| issn | 0923-7534 1569-8041 |
| language | eng |
| recordid | cdi_crossref_primary_10_1093_annonc_mdx377_008 |
| source | Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Alma/SFX Local Collection |
| title | (Neo-)adjuvant ipilimumab + nivolumab (IPI+NIVO) in palpable stage 3 melanoma – updated relapse free survival (RFS) data from the OpACIN trial and first biomarker analyses |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-23T19%3A21%3A53IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-elsevier_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=(Neo-)adjuvant%20ipilimumab%20+%20nivolumab%20(IPI+NIVO)%20in%20palpable%20stage%203%20melanoma%20%E2%80%93%20updated%20relapse%20free%20survival%20(RFS)%20data%20from%20the%20OpACIN%20trial%20and%20first%20biomarker%20analyses&rft.jtitle=Annals%20of%20oncology&rft.au=Rozeman,%20E.A.&rft.date=2017-09&rft.volume=28&rft.spage=v432&rft.epage=v432&rft.pages=v432-v432&rft.issn=0923-7534&rft.eissn=1569-8041&rft_id=info:doi/10.1093/annonc/mdx377.008&rft_dat=%3Celsevier_cross%3ES0923753420384842%3C/elsevier_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rft_els_id=S0923753420384842&rfr_iscdi=true |